About Baxter International (NYSE:BAX)
Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.
Industry, Sector and Symbol
Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
Trailing P/E Ratio52.5846153846154
Forward P/E Ratio24.59
Sales & Book Value
Annual Sales$10.56 billion
Price / Sales3.53
Cash Flow$3.50 per share
Price / Cash19.53
Book Value$15.22 per share
Price / Book4.49
Net Income$717 million
Return on Equity15.12%
Return on Assets8.23%
Baxter International (NYSE:BAX) Frequently Asked Questions
What is Baxter International's stock symbol?
Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."
How often does Baxter International pay dividends? What is the dividend yield for Baxter International?
Baxter International announced a quarterly dividend on Tuesday, February 20th. Investors of record on Friday, March 2nd will be paid a dividend of $0.16 per share on Monday, April 2nd. This represents a $0.64 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date of this dividend is Thursday, March 1st. View Baxter International's Dividend History.
How will Baxter International's stock buyback program work?
Baxter International announced that its Board of Directors has authorized a share repurchase program on Wednesday, February 21st 2018, which allows the company to buyback $1,500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company's board believes its shares are undervalued.
How were Baxter International's earnings last quarter?
Baxter International Inc (NYSE:BAX) announced its quarterly earnings data on Thursday, February, 1st. The medical instruments supplier reported $0.64 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.59 by $0.05. The medical instruments supplier earned $2.77 billion during the quarter, compared to analysts' expectations of $2.77 billion. Baxter International had a return on equity of 15.12% and a net margin of 6.79%. Baxter International's revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.57 earnings per share. View Baxter International's Earnings History.
When will Baxter International make its next earnings announcement?
What guidance has Baxter International issued on next quarter's earnings?
Baxter International updated its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of $2.72-2.80 for the period, compared to the Thomson Reuters consensus estimate of $2.72. The company issued revenue guidance of +6-7% (Approx $11.2-11.3 billion), compared to the consensus revenue estimate of $11.10 billion.Baxter International also updated its Q1 guidance to $0.60-0.62 EPS.
Where is Baxter International's stock going? Where will Baxter International's stock price be in 2018?
15 brokerages have issued twelve-month price objectives for Baxter International's stock. Their forecasts range from $62.00 to $80.00. On average, they anticipate Baxter International's stock price to reach $71.62 in the next twelve months. View Analyst Ratings for Baxter International.
Who are some of Baxter International's key competitors?
Some companies that are related to Baxter International include Covidien (COV), C R Bard (BCR), Zimmer Biomet (ZBH), Align Technology (ALGN), DENTSPLY SIRONA (XRAY), CareFusion (CFN), Steris (STE), Bio-Rad Laboratories (BIO), West Pharmaceutical Services (WST), Hill-Rom (HRC), DexCom (DXCM), Globus Medical (GMED), ICU Medical (ICUI), VWR (VWR), Integra Lifesciences (IART), LivaNova (LIVN), Haemonetics (HAE) and Neogen (NEOG).
Who are Baxter International's key executives?
Baxter International's management team includes the folowing people:
- Jose E. Almeida, Chairman of the Board, President, Chief Executive Officer (Age 55)
- James K. Saccaro, Corporate Vice President and Chief Financial Officer (Age 44)
- Giuseppe Accogli, Senior Vice President, President - Global Businesses (Age 46)
- Brik V. Eyre, Senior Vice President, President - Americas (Age 53)
- Marcus Schabacker M.D. Ph.D., Chief Scientific Officer, Corporate Vice President (Age 53)
- Scott Pleau, Corporate Vice President - Operations (Age 51)
- Sean Martin, Corporate Vice President, General Counsel
- Jeanne K. Mason Ph.D., Corporate Vice President - Human Resources (Age 61)
- Paul Vibert, Corporate Vice President, President - International (Age 57)
- Thomas T. Stallkamp, Lead Independent Director (Age 70)
Who owns Baxter International stock?
Baxter International's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.69%), Geode Capital Management LLC (1.07%), Bank of New York Mellon Corp (0.91%), APG Asset Management N.V. (0.89%), Bessemer Group Inc. (0.69%) and Two Sigma Advisers LP (0.68%). Company insiders that own Baxter International stock include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, Jeanne K Mason, John D Forsyth, Jose E Almeida, Peter S Hellman, Third Point Llc and Thomas T Stallkamp. View Institutional Ownership Trends for Baxter International.
Who sold Baxter International stock? Who is selling Baxter International stock?
Baxter International's stock was sold by a variety of institutional investors in the last quarter, including Aristotle Capital Management LLC, BlackRock Inc., Thunderbird Partners LLP, Bessemer Group Inc., CI Global Investments Inc., First Trust Advisors LP, American Century Companies Inc. and Bank of Montreal Can. Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Brik V Eyre, Carole J Shapazian, Giuseppe Accogli, James R Gavin III, Jeanne K Mason, John D Forsyth, Third Point Llc and Thomas T Stallkamp. View Insider Buying and Selling for Baxter International.
Who bought Baxter International stock? Who is buying Baxter International stock?
Baxter International's stock was bought by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, HealthCor Management L.P., Amundi Pioneer Asset Management Inc., Renaissance Technologies LLC, Old Mutual Global Investors UK Ltd., Acadian Asset Management LLC, Shell Asset Management Co. and Teacher Retirement System of Texas. View Insider Buying and Selling for Baxter International.
How do I buy Baxter International stock?
Shares of Baxter International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Baxter International's stock price today?
One share of Baxter International stock can currently be purchased for approximately $68.36.
How big of a company is Baxter International?
Baxter International has a market capitalization of $37.24 billion and generates $10.56 billion in revenue each year. The medical instruments supplier earns $717 million in net income (profit) each year or $1.30 on an earnings per share basis. Baxter International employs 48,000 workers across the globe.
How can I contact Baxter International?
Baxter International's mailing address is 1 Baxter Pkwy, DEERFIELD, IL 60015-4625, United States. The medical instruments supplier can be reached via phone at +1-847-9482000 or via email at [email protected]
MarketBeat Community Rating for Baxter International (BAX)MarketBeat's community ratings are surveys of what our community members think about Baxter International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Baxter International (NYSE:BAX) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.73||2.71||2.58||2.58|
|Ratings Breakdown: ||0 Sell Rating(s)|
5 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
|1 Sell Rating(s)|
4 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$71.62||$68.92||$67.55||$65.55|
|Price Target Upside: ||7.97% upside||2.60% upside||5.47% upside||6.82% upside|
Baxter International (NYSE:BAX) Consensus Price Target History
Baxter International (NYSE:BAX) Analyst Ratings History
(Data available from 2/24/2016 forward)
Baxter International (NYSE:BAX) Earnings History and Estimates Chart
Baxter International (NYSE BAX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/1/2018||Q4 2017||$0.59||$0.64||$2.77 billion||$2.77 billion||View||Listen|
|10/25/2017||Q3 2017||$0.59||$0.64||$2.66 billion||$2.71 billion||View||N/A|
|7/26/2017||Q2 2017||$0.57||$0.63||$2.59 billion||$2.61 billion||View||N/A|
|4/26/2017||Q1 2017||$0.51||$0.58||$2.43 billion||$2.48 billion||View||N/A|
|2/1/2017||Q416||$0.52||$0.57||$2.65 billion||$2.65 billion||View||Listen|
|10/25/2016||Q316||$0.45||$0.56||$2.67 billion||$2.56 billion||View||Listen|
|7/26/2016||Q216||$0.40||$0.46||$2.51 billion||$2.60 billion||View||Listen|
|4/26/2016||Q116||$0.29||$0.36||$2.35 billion||$2.40 billion||View||Listen|
|2/2/2016||Q415||$0.32||$0.43||$2.55 billion||$2.60 billion||View||Listen|
|10/27/2015||Q315||$0.29||$0.41||$2.46 billion||$2.49 billion||View||Listen|
|7/29/2015||Q215||$0.94||$1.00||$2.40 billion||$3.90 billion||View||Listen|
|4/23/2015||Q115||$0.88||$1.00||$3.70 billion||$3.76 billion||View||Listen|
|1/29/2015||Q414||$1.31||$1.34||$4.37 billion||$4.47 billion||View||Listen|
|10/16/2014||Q314||$1.31||$1.31||$4.21 billion||$4.20 billion||View||Listen|
|7/17/2014||Q214||$1.21||$1.26||$4.12 billion||$4.30 billion||View||Listen|
|4/17/2014||Q114||$1.10||$1.19||$3.88 billion||$3.95 billion||View||Listen|
|1/23/2014||Q413||$1.25||$1.26||$4.25 billion||$4.40 billion||View||Listen|
|10/17/2013||Q313||$1.19||$1.19||$3.82 billion||$3.80 billion||View||Listen|
|7/18/2013||Q2 2013||$1.13||$1.16||$3.70 billion||$3.67 billion||View||Listen|
|4/18/2013||Q1 2013||$1.04||$1.05||$3.49 billion||$3.45 billion||View||Listen|
|1/24/2013||Q4 2012||$1.26||$1.26||$3.72 billion||$3.75 billion||View||Listen|
Baxter International (NYSE:BAX) Earnings Estimates
2018 EPS Consensus Estimate: $2.78
2019 EPS Consensus Estimate: $3.10
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Baxter International (NYSE:BAX) Dividend Information
|Dividend Growth:||-34.00% (3 Year Average)|
|Payout Ratio:||49.23% (Trailing 12 Months of Earnings) |
23.02% (Based on This Year's Estimates)
20.71% (Based on Next Year's Estimates)
Baxter International (NYSE:BAX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Baxter International (NYSE BAX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.05%
Institutional Ownership Percentage: 84.96%
Baxter International (NYSE BAX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/2/2018||Giuseppe Accogli||SVP||Sell||28,641||$67.00||$1,918,947.00|| |
|12/4/2017||Jeanne K Mason||SVP||Sell||33,350||$65.25||$2,176,087.50||124,609|| |
|11/6/2017||Third Point Llc||Director||Sell||5,000,000||$64.23||$321,150,000.00|| |
|9/5/2017||Thomas T Stallkamp||Director||Sell||8,920||$62.28||$555,537.60||16,263|| |
|8/25/2017||John D Forsyth||Director||Sell||9,440||$61.76||$583,014.40||32,444|| |
|8/24/2017||Carole J Shapazian||Director||Sell||4,020||$61.61||$247,672.20||13,868|| |
|8/17/2017||Giuseppe Accogli||SVP||Sell||12,670||$60.96||$772,363.20||33,286|| |
|5/23/2017||Carole J Shapazian||Director||Sell||2,618||$57.92||$151,634.56||9,848|| |
|5/9/2017||Carole J Shapazian||Director||Sell||3,760||$55.89||$210,146.40||16,226|| |
|5/8/2017||Brik V Eyre||SVP||Sell||130,732||$55.69||$7,280,465.08||49,966|| |
|4/10/2017||Albert P L Stroucken||Director||Sell||4,280||$52.80||$225,984.00||25,667|| |
|3/29/2017||James R Gavin III||Director||Sell||4,280||$51.72||$221,361.60||34,980|| |
|2/22/2017||Peter S Hellman||Director||Sell||4,280||$49.81||$213,186.80||24,420|| |
|2/8/2017||John D Forsyth||Director||Sell||4,280||$48.35||$206,938.00||31,338|| |
|5/23/2016||Jose E Almeida||CEO||Buy||11,691||$42.75||$499,790.25||11,691|| |
|5/2/2016||John D Forsyth||Director||Sell||1,887||$44.38||$83,745.06||26,320|| |
|4/4/2016||John D Forsyth||Director||Sell||1,887||$41.75||$78,782.25||26,315|| |
|3/14/2016||James R Gavin III||Director||Sell||5,660||$40.34||$228,324.40||33,432|| |
|2/17/2016||Peter S. Hellman||Director||Sell||5,660||$38.35||$217,061.00||17,520|| |
|2/11/2016||Kornelis J. Storm||Director||Sell||5,660||$35.98||$203,646.80||19,191|| |
|5/22/2015||Carole J Shapazian||Director||Sell||1,533||$67.68||$103,753.44|| |
|4/27/2015||James R Gavin III||Director||Sell||4,830||$71.06||$343,219.80|| |
|7/25/2014||Carole J Shapazian||Director||Sell||1,645||$76.98||$126,632.10|| |
|7/24/2014||Thomas T Stallkamp||Director||Sell||8,300||$76.82||$637,606.00|| |
|7/9/2014||Ludwig Hantson||VP||Sell||24,693||$76.00||$1,876,668.00|| |
|5/2/2014||Carole Shapazian||Director||Sell||5,680||$75.28||$427,590.40||5,146|| |
|4/23/2014||Kees Storm||Director||Sell||5,760||$72.45||$417,312.00||15,156|| |
|4/21/2014||Blake Devitt||Director||Sell||4,334||$73.12||$316,902.08||16,541|| |
|3/27/2014||Sebastian Bufalino||VP||Sell||21,600||$75.10||$1,622,160.00||6,275|| |
|9/12/2013||Carole Shapazian||Director||Sell||1,941||$71.58||$138,936.78||5,111|| |
|8/1/2013||Robert L Parkinson Jr||CEO||Sell||725,750||$73.33||$53,219,247.50|| |
|7/26/2013||David P Scharf||VP||Sell||55,438||$73.79||$4,090,770.02|| |
|7/25/2013||James R Gavin III||Director||Sell||5,760||$72.82||$419,443.20|| |
|7/24/2013||Carole J Shapazian||Director||Sell||4,320||$73.58||$317,865.60|| |
|7/22/2013||Robert J Hombach||CFO||Sell||47,452||$73.95||$3,509,075.40|| |
|7/16/2013||Phillip L Batchelor||VP||Sell||5,850||$73.00||$427,050.00|| |
|5/22/2013||Blake E Devitt||Director||Sell||1,000||$72.34||$72,340.00|| |
|5/20/2013||Sebastian J Bufalino||VP||Sell||24,000||$73.75||$1,770,000.00|| |
|5/17/2013||Robert M Davis||VP||Sell||130,800||$73.00||$9,548,400.00|| |
|9/13/2012||Michael J Baughman||VP||Sell||11,500||$61.00||$701,500.00|| |
Baxter International (NYSE BAX) News Headlines
Baxter International (NYSE:BAX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Baxter International (NYSE:BAX) Income Statement, Balance Sheet and Cash Flow Statement
Baxter International (NYSE BAX) Stock Chart for Saturday, February, 24, 2018